Wyss, DFCI, MGH logosHSE, HSCI logos
Harvard i3 Center: Biomaterials to Create T Cell Immunity
Wyss Institute at Harvard University

Dana-Farber Cancer Immunology Seminar Series

Dana Farber Cancer Immunology Seminar Series Logo

Time: 1:00 pm - 2:00 pm
Zoom link: https://dfci.zoom.us/j/91621307314?pwd=KzQzRWI3azFKdnNVa2VYOXBOYy9nUT09
Passcode: 757346

Date and Time Speaker Institution Seminar Title
Adam Bass, MD Dana-Farber Cancer Institute Unexpected immune interactions from studies of lineage oncogenes in squamous cell carcinoma
Alexander Marson University of California, San Francisco Programming T Cell Therapies with CRISPR
Amanda Lund, PhD NYU Langone Health Investigating the Immunological Implications of Lymphatic Transport in Skin and Melanoma
Amy Moran Oregon Health & Science University
Andrew Kruse, PhD Harvard Medical School Antibody Fragments as Tools to Interrogate G protein-coupled Receptor Signaling
Andy Minn, MD, PhD University of Pennsylvania Decoding and Recoding the Opposing Roles of Interferon and Pattern Recognition Receptor Signaling in Cancer Immunotherapy
Ankur Singh, PhD Georgia Institute of Technology Organoids to study cooperative signaling, epigenetics, and therapeutic resistance in human cancers
(Co-sponsored by the Harvard i3 Center and DFCI )
Bronwyn MacInnis and Katie Siddle, PhDs Broad Institute Genomic Epidemiology of SARS-CoV-2 in Massachusetts
Caetano Reis e Sousa, DPhil The Francis Crick Institte
Caroline Sokol, MD, PhD Massachusetts General Hospital Neuro-immune Recognition of Allergens
Carrie Lucas, Ph.D. Yale University Immunobiology Illuminated by Pediatric Inflammatory Disorders
Christina Towers Salk Institute Mechanisms to Circumvent Autophagy Inhibition in Cancer
Cigall Kadoch, PhD Dana-Farber Cancer Institute Structure and Function of Mammalian SWI/SNF Chromatin Remodeling Complexes in Human Cancer
Dan Barouch, MD, PhD Beth Israel Deaconess Medical Center COVID-19: Developing a Vaccine During a Pandemic
Daniel McVicar NIH
Daniel Schramek, PhD Lunenfeld/Tanenbaum Research Institute In Vivo Veritas – using CRISPR to Delineate Cancer Genes and Immune Regulators
Darrell Irvine, PhD MIT Engineering Timing and Location of Immunotherapy to Enhance Anti-Tumor Immunity
(Co-sponsored by the Harvard i3 Center and DFCI )
David Knipe, PhD Harvard Medical School Linking Adaptive Immunity to Epigenetic Silencing of Herpesviruses
Dr. Suzie Pun University of Washington Biomaterials for Immunoengineering
(Co-sponsored by the Harvard i3 Center and DFCI )
Edward Chouchani, PhD Dana-Farber Cancer Institute Mechanisms of Metabolite Regulation Over Health & Disease
Federica Sallusto, PhD ETH Zurich One for All: Cross-Reactive T Cells and Antibodies to Coronaviruses
Florian Schmidt, PhD Univeristy of Bonn Interrogating Infection and Immunity with Camelid Nanobodies
Francisco Quintana, PhD Brigham and Women's Hospital Immunosuppressive Astrocyte Subsets
Gerhard Wagner, PhD Harvard Medical School Cytocapsular Tubes: New Dimension in Cancer Biology and Treatment
Gwendalyn Randolph, PhD Washington University
Ioannis Zervantonakis, PhD University of Pittsburgh Modeling Cell-Cell Interactions in the Tumor Microenvironment Using Microfluidics
(Co-sponsored by the Harvard i3 Center and DFCI )
James Moon, PhD University of Michigan Engineering Strategies to Modulate the Gut Microbiome and Immune System
(Co-sponsored by the Harvard i3 Center and DFCI )
Jeffrey Hubbell, PhD University of Chicago Cytokine Engineering to Modulate the Tumor Microenvironment
(Co-sponsored by the Harvard i3 Center and DFCI )
Jessica Thaxton, PhD University of North Carolina Stress-Mediated Attenuation of Translation Undermines T Cell Tumor Control
Joan Brugge, PhD Harvard Medical School
Jose Ordovas-Montanes, PhD Boston Children's Hospital Single-Cell Biology of Barrier Tissues and COVID-19
Julie Magarian Blander, PhD Cornell University Regulation of Cross-Presentation by Dendritic Cells
Justin Eyquem University of California, San Francisco
Kate Jeffrey, PhD Massachusetts General Hospital Epigenome and Virome Immunomodulation in the Gut
Katelyn Byrne, PhD Parker Institute for Cancer Immunotherapy Strategies for Overcoming the Suppressive Pancreatic Tumor Microenvironment
Ken Murphy Washington University in St. Louis Development and Dynamic Regulation of cDC1 in Homeostasis and Cancer
Kevin Haigis, PhD Dana-Farber Cancer Institute Pathogenic Epithelial-Immune Interactions in the Gastrointestinal Tract
Kole Roybal University of California, San Francisco
Luke Gilbert, PhD UCSF Modeling Human Genetic Interactions and Disease at Single Cell Resolution Using CRISPR Functional Genomics
Manuel Valiente, PhD Centro Nacional de Investigaciones Oncológicas Strategies to Challenge Brain Metastatis Lethality in Mice and Human
Marcia Haigis, PhD Harvard Medical School
Maria Rescigno, PhD Humanitas University The Microbiota in Cancer Progression and Treatment
Markus Frank, MD Boston Children's Hospital ABCB5-Mediated Cancer Resistance to Targeted and Immunotherapeutic Treatment Modalities
Matthew Vander Heiden, MD, PhD MIT Environmental Influence on Tumor Metabolism
Matthias Stephan, MD, PhD Fred Hutchinson Cancer Research Center Creating Living Drugs with Synthetic Compounds
(Co-sponsored by the Harvard i3 Center and DFCI )
Michael Birnbaum, PhD MIT Decoding Immune Recognition
Michael Dougan, MD, PhD Massachusetts General Hospital Using Immunotherapy to Understand Immune Regulation in the Gut
Michael Dustin Oxford University Engaging the Immunological Synapse in Cancer Therapy
Michele De Palma EPFL (Swiss Federal Institute of Technology in Lausanne)
Michelle Kelliher, PhD UMass Chan Medical School Understanding Glucocorticoid Resistance and Relapse in T-ALL Mouse Models
Nina Bhardwaj, MD, PhD Mount Sinai Overcoming Resistance to Immunotherapy: Targeting Innate Immune Cells
Professor Samir Mitragotri Harvard John A. Paulson School of Engineering & Applied Sciences (Co-sponsored by the Harvard i3 Center and DFCI )
Pulin Li, PhD MIT Spatial Control of Cell-Cell Communication: From Genes to Circuits
Robert Seder, MD National Institutes of Health Peptide-TLR-7/8 Agonist Vaccine is a Tunable Platform for Altering the Magnitude, Quality and Breadth of Neoantigen CD8 T Cell Responses
(Co-sponsored by the Harvard i3 Center and DFCI )
Seth Rakoff-Nahoum, MD, PhD Boston Children's Hospital
Sloan Devlin, PhD Harvard Medical School Gut Bacterial Modification of Bile Acids Alters Host Physiology
Stefani Spranger, PhD MIT The impact of dendritic cells on anti-tumor T cell responses
Stefanie Vogel, PhD University of Maryland Targeting Host Responses to Mitigate Influenza-induced Severe Disease
Viviana Cremasco, PhD Novartis Institutes for Biomedical Research Stroma-imposed immune regulation
William Sellers, MD Broad Institute Functional Genomic Approaches to the Discovery of Paralog Dependencies in Cancer
Yvonne Chen, Ph.D. University of California, Los Angeles Engineering Next-Generation CAR-T Cell Therapy for Cancer
(Co-sponsored by the Harvard i3 Center and DFCI )
The i3 Center is supported by the National Cancer Institute(NCI) and the National Institute On Aging (NIA) of the National Institutes of Health under Award Number U54CA244726. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Copyright © The President and Fellows of Harvard College